http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2296593-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4c66f2bfd4310c00317d8e1681d4b0ba http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d40960190e37af1e3390c21a67554f98 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_153ae69eed34c3caf715379b30dd185f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_648c15a91ad38a5e43585ef62955658b |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N2-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N2-06 |
| filingDate | 2005-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2007-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_20dcefa2d46081b24c6321b5f6e0f38c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_902e391327ed3d136ade800bdf4dbb13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d49b717ab3b90ca404fbb56dd6c06c72 |
| publicationDate | 2007-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2296593-C1 |
| titleOfInvention | Method for treating mammary gland cancer |
| abstract | FIELD: medicine, oncology. n SUBSTANCE: during the first day of therapy it is necessary to affect the lesion focus with alternating magnetic field at induction being 5-160 mTl, frequency of 50-100 Hz for about 7-10 min. Out of peripheral vein one should sample blood into two vials with hemoconservant per 100 ml/each; one vial should be supplemented with doxorubicin at the dosage of 50 mg/sq. m, the second vial - with 5-fluorouracil 750 mg/sq. m. Both vials should be incubated. Then it is necessary to inject intravenously by drops the content of the first, and then of the second vial for a patient. During the period since the first day up to the seventh one it is necessary to introduce cyclophosphan intramuscularly per 200 mg/sq. m. Since the first up to the tenth day of therapy one should affect with alternating and direct magnetic field. On the eighth day after seances of magnetic therapy one should repeatedly introduce anti-tumor chemopreparations at the same dosages and sequence. In two weeks it is necessary to repeat the above-mentioned curative impacts. In two weeks after the last introduction of chemopreparations one should fulfill surgical removal of lesion focus. The innovation enables to avoid side toxic manifestations of chemopreparations and notching of sutures and, also, healing due to secondary tension. n EFFECT: higher efficiency of therapy. n 1 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2563369-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2581946-C2 |
| priorityDate | 2005-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 26.